Premium
Impact of Pharmacometric Reviews on New Drug Approval and Labeling Decisions—a Survey of 31 New Drug Applications Submitted Between 2005 and 2006
Author(s) -
Bhattaram V A,
Bonapace C,
Chilukuri D M,
Duan J Z,
Garnett C,
Gobburu J V S,
Jang S H,
Kenna L,
Lesko L J,
Madabushi R,
Men Y,
Powell J R,
Qiu W,
Ramchandani R P,
Tornoe C W,
Wang Y,
Zheng J J
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100051
Subject(s) - drug , medicine , drug approval , pharmacology
Exploratory analyses of data pertaining to pharmacokinetic, pharmacodynamic, and disease progression are often referred to as the pharmacometrics (PM) analyses. The objective of the current report is to assess the role of PM, at the Food and Drug Administration (FDA), in drug approval and labeling decisions. We surveyed the impact of PM analyses on New Drug Applications (NDAs) reviewed over 15 months in 2005–2006. The survey focused on both the approval and labeling decisions through four perspectives: clinical pharmacology primary reviewer, their team leader, the clinical team member, and the PM reviewer. A total of 31 NDAs included a PM review component. Review of NDAs involved independent quantitative evaluation by FDA pharmacometricians. PM analyses were ranked as important in regulatory decision making in over 85% of the 31 NDAs. Case studies are presented to demonstrate the applications of PM analysis. Clinical Pharmacology & Therapeutics (2007) 81 , 213–221. doi: 10.1038/sj.clpt.6100051